Several clinical trials are underway to evaluate the clinical efficacy of crenolanib, including a randomized phase III trial evaluating the potency of crenolanib in combination with induction chemotherapy for relapsed or refractory FLT3-mutated AML patients (NCT02298166) and a multicentre phase III trial comparing the effects of crenolanib with midostaurin during induction chemotherapy and consolidation therapy for newly diagnosed FLT3-mutated AML patients (NCT03258931). Here, FLT3 is linked to acute myeloid leukemia.